Tourette Syndrome-Pipeline Review, H2 2015

Tourette Syndrome-Pipeline Review, H2 2015

  • Products Id :- GMDHC7011IDB
  • |
  • Pages: 72
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Tourette Syndrome-Pipeline Review, H2 2015


Global Markets Direct's, 'Tourette Syndrome-Pipeline Review, H2 2015', provides an overview of the Tourette Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Tourette Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tourette Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Tourette Syndrome

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Tourette Syndrome and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Tourette Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Tourette Syndrome pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Tourette Syndrome

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Tourette Syndrome pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Tourette Syndrome Overview 6

Therapeutics Development 7

Pipeline Products for Tourette Syndrome-Overview 7

Pipeline Products for Tourette Syndrome-Comparative Analysis 8

Tourette Syndrome-Therapeutics under Development by Companies 9

Tourette Syndrome-Pipeline Products Glance 10

Clinical Stage Products 10

Unknown Stage Products 11

Tourette Syndrome-Products under Development by Companies 12

Tourette Syndrome-Companies Involved in Therapeutics Development 13

AstraZeneca Plc 13

Catalyst Pharmaceutical Partners, Inc. 14

Edison Pharmaceuticals, Inc. 15

Neurocrine Biosciences, Inc. 16

Psyadon Pharmaceuticals, Inc. 17

Reviva Pharmaceuticals Inc. 18

Synchroneuron Inc. 19

Teva Pharmaceutical Industries Limited 20

Tourette Syndrome-Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Target 22

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 27

Drug Profiles 28

acamprosate calcium SR-Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

AZD-5213-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

CPP-115-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

dutetrabenazine ER-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

ecopipam hydrochloride-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

RP-5063-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

valbenazine-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

vatiquinone-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

vigabatrin-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Tourette Syndrome-Recent Pipeline Updates 46

Tourette Syndrome-Dormant Projects 63

Tourette Syndrome-Discontinued Products 64

Tourette Syndrome-Product Development Milestones 65

Featured News & Press Releases 65

Jan 14, 2015: Auspex Pharmaceuticals Receives FDA Orphan Drug Designation of SD-809 for Treatment of Tourette Syndrome in the Pediatric Population 65

Oct 02, 2014: Neurocrine Announces Expansion Of VMAT2 Inhibitor Program With Initiation Of Tourette Syndrome Clinical Study 65

May 28, 2014: Psyadon Announces the Opening of a New Clinical Trial of Ecopipam for the Treatment of Tourette's Syndrome in Children Ages 7-17 66

Jul 24, 2012: Psyadon Announces Positive Interim Analysis Of Phase II Study Of Ecopipam For Treatment Of Tourette Syndrome 67

Sep 19, 2011: Neurocrine Biosciences Initiates Phase II Clinical Trial Of NBI-98854 68

May 11, 2011: Tourette Syndrome Association And Psyadon Pharma To Collaborate On Drug Trial For Tourette Syndrome Treatment 68

Apr 13, 2010: Neurocrine Biosciences Begins Second VMAT2 Phase I Clinical Trial 69

Appendix 71

Methodology 71

Coverage 71

Secondary Research 71

Primary Research 71

Expert Panel Validation 71

Contact Us 71

Disclaimer 72

List of Tables

Number of Products under Development for Tourette Syndrome, H2 2015 7

Number of Products under Development for Tourette Syndrome-Comparative Analysis, H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Comparative Analysis by Clinical Stage Development, H2 2015 10

Comparative Analysis by Unknown Stage Development, H2 2015 11

Products under Development by Companies, H2 2015 12

Tourette Syndrome-Pipeline by AstraZeneca Plc, H2 2015 13

Tourette Syndrome-Pipeline by Catalyst Pharmaceutical Partners, Inc., H2 2015 14

Tourette Syndrome-Pipeline by Edison Pharmaceuticals, Inc., H2 2015 15

Tourette Syndrome-Pipeline by Neurocrine Biosciences, Inc., H2 2015 16

Tourette Syndrome-Pipeline by Psyadon Pharmaceuticals, Inc., H2 2015 17

Tourette Syndrome-Pipeline by Reviva Pharmaceuticals Inc., H2 2015 18

Tourette Syndrome-Pipeline by Synchroneuron Inc., H2 2015 19

Tourette Syndrome-Pipeline by Teva Pharmaceutical Industries Limited, H2 2015 20

Assessment by Monotherapy Products, H2 2015 21

Number of Products by Stage and Target, H2 2015 23

Number of Products by Stage and Mechanism of Action, H2 2015 25

Number of Products by Stage and Route of Administration, H2 2015 26

Number of Products by Stage and Molecule Type, H2 2015 27

Tourette Syndrome Therapeutics-Recent Pipeline Updates, H2 2015 46

Tourette Syndrome-Dormant Projects, H2 2015 63

Tourette Syndrome-Discontinued Products, H2 2015 64

List of Figures

Number of Products under Development for Tourette Syndrome, H2 2015 7

Number of Products under Development for Tourette Syndrome-Comparative Analysis, H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Comparative Analysis by Clinical Stage Development, H2 2015 10

Assessment by Monotherapy Products, H2 2015 21

Number of Products by Top 10 Targets, H2 2015 22

Number of Products by Stage and Top 10 Targets, H2 2015 22

Number of Products by Top 10 Mechanism of Actions, H2 2015 24

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 24

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 26

Number of Products by Stage and Top 10 Molecule Types, H2 2015 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

AstraZeneca Plc

Catalyst Pharmaceutical Partners, Inc.

Edison Pharmaceuticals, Inc.

Neurocrine Biosciences, Inc.

Psyadon Pharmaceuticals, Inc.

Reviva Pharmaceuticals Inc.

Synchroneuron Inc.

Teva Pharmaceutical Industries Limited

Tourette Syndrome Therapeutic Products under Development, Key Players in Tourette Syndrome Therapeutics, Tourette Syndrome Pipeline Overview, Tourette Syndrome Pipeline, Tourette Syndrome Pipeline Assessment

select a license

Single User License
USD 2000 INR 135980
Site License
USD 4000 INR 271960
Corporate User License
USD 6000 INR 407940



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]